B3Preservation of lymphocyte functional fitness in perinatally-infected HIV+ pediatric patients with sub-optimal viral controlE-posterDeterminants of HIV progression and disease control
B30Rising substance use linked to STI and HCV in Thai MSM after acute HIV infectionOn-demand oral abstract sessionSubstance abuse (including opioid use disorder)
B30Opioid agonist treatment improves progression through each stage of the HIV cascade of care among people living with HIV who use opioidsE-posterSubstance abuse (including opioid use disorder)
B30Depression, anxiety, and polysubstance use among persons with HIV: baseline findings from the Promoting Access to Care Engagement (PACE) trialE-posterSubstance abuse (including opioid use disorder)
B30Results from a randomized controlled trial of smoking cessation medications for alcohol reduction among HIV-positive heavy drinkers and daily smokers in St. Petersburg, RussiaE-posterSubstance abuse (including opioid use disorder)
B30Anxiety and alcohol consumption in the Miami Adult Studies on HIV (MASH) cohort during the COVID-19 pandemicE-posterSubstance abuse (including opioid use disorder)
B31OPTIPRIM 2-ANRS trial comparing dolutegravir vs darunavir in acute HIV-1 infectionE-posterART in acute infection
B32Integrase strand transfer inhibitor (INSTI) use and cancer incidenceE-posterART in first- and second-line therapies
B32Antiretroviral therapy for HIV controllers: indications and outcomes in the French ANRS-CO21 CODEX cohortE-posterART in first- and second-line therapies
B32Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine?E-posterART in first- and second-line therapies
171 - 180 of 870 items